NEOPROBE CORP
10-Q, EX-27.1, 2000-08-11
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: NEOPROBE CORP, 10-Q, EX-11.1, 2000-08-11
Next: ANDOVER BANCORP INC, 10-Q, 2000-08-11



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                       2,706,596
<SECURITIES>                                         0
<RECEIVABLES>                                2,217,611
<ALLOWANCES>                                    94,429
<INVENTORY>                                    331,899
<CURRENT-ASSETS>                             5,632,315
<PP&E>                                       2,317,669
<DEPRECIATION>                               1,413,648
<TOTAL-ASSETS>                               7,307,551
<CURRENT-LIABILITIES>                        2,892,333
<BONDS>                                         80,501
                                0
                                          0
<COMMON>                                        26,241
<OTHER-SE>                                   1,708,476
<TOTAL-LIABILITY-AND-EQUITY>                 7,307,551
<SALES>                                      4,117,470
<TOTAL-REVENUES>                             4,567,470
<CGS>                                        2,282,025
<TOTAL-COSTS>                                2,282,025
<OTHER-EXPENSES>                               375,354
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              15,967
<INCOME-PRETAX>                                612,451
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            612,451
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   612,451
<EPS-BASIC>                                     (0.01)
<EPS-DILUTED>                                   (0.01)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission